Scarica l'app Stockscreener
93.05
1.22%
-1.15
Precedente Chiudi:
$94.20
Aprire:
$96.7
Volume 24 ore:
473.49K
Relative Volume:
1.11
Capitalizzazione di mercato:
$1.37B
Reddito:
$1.30M
Utile/perdita netta:
$-140.06M
Rapporto P/E:
-10.29
EPS:
-9.0441
Flusso di cassa netto:
$-129.83M
1 W Prestazione:
-0.52%
1M Prestazione:
-12.05%
6M Prestazione:
+9.06%
1 anno Prestazione:
+511.77%
Intervallo 1D:
$91.18
$99.33
Intervallo di 1 settimana:
$88.63
$99.33
Portata 52W:
$13.97
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
93.05 | 1.37B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences Inc (INBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibrx Biosciences Inc (INBX) Institutional Confidence - TradingKey
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibrx Biosciences Inc (INBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy - TipRanks
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy - Stock Titan
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com - Investing.com Australia
FDA accepts Inhibrx Biosciences filing for ozekibart in metastatic chondrosarcoma - Traders Union
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com South Africa
Inhibrx Biosciences stock gains after FDA accepts drug filing - Investing.com
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PR Newswire
Number of shareholders of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
(INBX) Risk Channels and Responsive Allocation - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Stock Gains on Operational UpdatesRetail Earnings Report - newsline.com
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike - Stock Titan
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options - Stock Titan
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22 - Stock Titan
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting - TipRanks
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO - Stock Titan
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Stifel reiterates Inhibrx Biosciences stock rating on durability data By Investing.com - Investing.com Canada
Inhibrx Biosciences targets research advances at ASCO26 to accelerate new cancer treatments - Traders Union
INBX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue R&D FocusEPS Growth Report - newsline.com
Inhibrx Biosciences (INBX) Slips 2% as Stock Tests Key Support Amid Biotech VolatilityVolatility Breakout Picks - The Legal Advocate
(INBX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Inhibrx Biosciences (INBX) Edges Higher as Stock Holds Above SupportRVOL Spike - The Legal Advocate
INBX Stock Price, Quote & Chart | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences (INBX) Surges Over 5% as Biotech Momentum BuildsCollar Trade - thelegaladvocate.com
How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story - Sahm
Inhibrx Biosciences Hits Day Low of $99.70 Amid Price Pressure - MarketsMojo
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx Inc stock (US45720L1070): trial update around ozekibart keeps biotech investors watching - AD HOC NEWS
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation - AASTOCKS.com
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study - MSN
Inhibrx Biosciences, Inc.Common Stock (NQ: INBX - The Chronicle-Journal
This biotech stock surges after positive cancer trial results. What to know. - MSN
Liquidity Mapping Around (INBX) Price Events - Stock Traders Daily
Inhibrx cancer treatment shows high response rates in head and neck cancer study - MSN
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter - Stock Titan
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A - Stock Titan
Inhibrx Biosciences 1Q Loss/Shr $2.15 >INBX - Moomoo
Inhibrx Reports First Quarter 2026 Financial Results - Arizona Daily Sun
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Inhibrx & Invesco Mortgage Capital Q1 2026 Results - Punjab Kesari English
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer - BioPharma APAC
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):